BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Amyloidosis (ATTR / AL) clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for amyloidosis: 100 (50 sponsors; 24 newly posted in the last 180 days, 5 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 24, rank 16 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 10, Phase 2 26, Phase 3 28, Phase 4 5, N/A 31.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Alnylam Pharmaceuticals ALNY | 9 | P3 4, P2 1, NA 4 | 0 | 0 |
| Eli Lilly and Company LLY | 9 | P3 4, P1 3, NA 1, P2 1 | 4 | 0 |
| Alexion Pharmaceuticals, Inc. | 6 | P4 1, P3 4, P2 1 | 1 | 0 |
| Eidos Therapeutics, a BridgeBio company | 4 | P3 3, P4 1 | 1 | 0 |
| Colgate Palmolive CL new entrant | 3 | P4 1, P3 2 | 3 | 2 |
| Intellia Therapeutics NTLA | 3 | NA 1, P3 2 | 0 | 0 |
| Ionis Pharmaceuticals, Inc. IONS | 2 | P3 2 | 0 | 0 |
| AstraZeneca AZN | 8 | NA 6, P3 1, P2 1 | 3 | 0 |
| Novo Nordisk A/S NVO | 3 | P3 1, P2 1, P1 1 | 0 | 0 |
| AbbVie ABBV | 2 | P3 1, P2 1 | 1 | 0 |
| Eisai Inc. | 2 | P3 1, NA 1 | 1 | 0 |
| Nexcella Inc. | 2 | P3 1, P2 1 | 1 | 1 |
| Regeneron Pharmaceuticals REGN | 2 | P3 1, P2 1 | 1 | 0 |
| Sinocelltech Ltd. | 1 | P3 1 | 0 | 0 |
| Bayer | 4 | NA 3, P4 1 | 1 | 0 |
| Janssen Research & Development, LLC | 3 | P1 2, P2 1 | 0 | 1 |
| Akcea Therapeutics | 2 | NA 2 | 0 | 0 |
| Galimedix Therapeutics Inc | 2 | P2 2 | 1 | 0 |
| Pfizer PFE | 2 | NA 2 | 0 | 1 |
| AC Immune SA ACIU | 1 | P2 1 | 0 | 0 |
| Alzamend Neuro, Inc. ALZN | 1 | P2 1 | 0 | 0 |
| Amydis Inc. | 1 | P2 1 | 0 | 1 |
| Arctic Therapeutics new entrant | 1 | P2 1 | 1 | 1 |
| Attralus, Inc. | 1 | P2 1 | 0 | 0 |
| Cenna Biosciences Inc. | 1 | P1 1 | 0 | 0 |
New-entrant sponsors: Colgate Palmolive, Arctic Therapeutics.
Recently stopped trials
- NCT06723171 Io Therapeutics - suspended: Sponsor request for study hold, funding issues Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis
- NCT06963216 Kedrion S.p.A. - withdrawn: Study was discontinued for non-safety reasons and the rapidly evolving treatment landscape for AL amyloidosis. A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
- NCT03536767 Eidos Therapeutics, a BridgeBio company - terminated: Study ended by the sponsor due to meeting Study Objectives Open-Label Study of AG10 in Patients With Cardiomyopathy
- NCT02952144 Kaneka Medical America LLC - suspended: Ongoing adjustments Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis
- NCT05839626 Sanofi - terminated: Early discontinuation based on sponsor decision not driven by any safety concerns; phase 2 was not initiated. A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRM
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Amydis Inc. | NCT05709314 A Study of AMDX-2011P in Participants With CAA | Cerebral Amyloid Angiopathy | recruiting | 25 |
| 2026-12 est. | P1/P2 | Nexcella Inc. | NCT06097832 Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | Light Chain (AL) Amyloidosis | active not recruiting | 45 |
| 2026-12-29 est. | P2 | Arctic Therapeutics | NCT07716865 Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA) | Hereditary Cystatin C Amyloid Angiopathy (HCCAA); Hemorrhage Brain; Hemorrhage Cerebral | active not recruiting | 15 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-11-27 | PDUFA date (company-disclosed) | pending | BridgeBio Pharma, Inc. BBIO | PDUFA November 27, 2026 - BridgeBio Pharma, Inc. |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P2 | Neurimmune AG | NCT07213583 Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM | Amyloid Transthyretin Cardiomyopathy | active not recruiting | 35 |
| 2026-09-28 est. | P2 | Attralus, Inc. | NCT05951049 A Study of AT-02 in Subjects With Systemic Amyloidosis. | Amyloidosis; Systemic | active not recruiting | 120 |
| 2026-09 est. | P3 | Eidos Therapeutics, a BridgeBio company | NCT04882735 Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | withdrawn | |
| 2026-06-30 est. | P2 | Keymed Biosciences Co.Ltd | NCT07039578 Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis | Primary Light-Chain Amyloidosis | recruiting | 90 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "amyloidosis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.